key: cord-0910237-6cvf68n1
authors: Goode, Jean-Venable R.; Page, Alexis; Burns, Anne; Bernard, Shaina; Wheawill, Stephanie; Gatewood, Sharon B.S.
title: The Pharmacist’s Role in SARS-CoV-2 Diagnostic Testing
date: 2020-08-11
journal: J Am Pharm Assoc (2003)
DOI: 10.1016/j.japh.2020.08.017
sha: db42a90b41a1a06410e81bfea6c0389b87a9cb14
doc_id: 910237
cord_uid: 6cvf68n1

Abstract The World Health Organization (WHO) has declared novel coronavirus disease 2019 (COVID-19) a global pandemic. A key component in stopping the spread of SARS-CoV2 is widespread testing, however, the United States (U.S.) continues to lag behind in available testing. Currently, several SARS-CoV-2 diagnostic tests are classified as waived tests under the Clinical Laboratory Amendments (CLIA) unlocking the opportunity for pharmacy-based laboratories to process tests. Furthermore, the U.S. Department of Health and Human Services (HHS) granted pharmacists the authority to order and administer tests for SARS-CoV-2. Even with this authority, it is uncertain how community-based pharmacists will implement SARS-CoV-2 testing in practice. This paper will provide a framework for pharmacist diagnostic testing for SARS-CoV-2 including a review of the currently available CLIA-waived tests, best practices for testing and a framework with testing models and potential payment opportunities. Pharmacists are the most accessible healthcare provider and have the knowledge and skills to assume a key role in increasing SARS-CoV-2 testing in the U.S.

issues. Pharmacies along with other private sector facilities and organizations should strive to maximize PPE through normal supply chains, exercising CDC recommendations conservation guidelines. 25 A distribution allocation may be determined by specific state/territorial health departments for pharmacists who are implementing community-based testing. The biggest challenge continues to be payment for pharmacist testing. Pharmacists should work with their local Medicare Administrative Contractors (MACs), State Medicaid and commercial payers to secure payment prior to testing. This article is intended to provide a framework for pharmacist SARS-CoV-2 diagnostic testing including a review of the currently available CLIA-waived tests, best practices for testing and a framework with models and potential payment opportunities.

The type of diagnostic tests for SARS-CoV-2 vary by item of detection, specimen sample, and clinical use (Table 1) . 10 Molecular-based diagnostic tests range in complexity from high complexity requiring skilled operators to collect the sample and manually perform the test to simple, automated tests available for use in CLIA-waived testing facilities. 10 CLIA-waived tests are deemed simple tests that require little manipulation with low risk for error or incorrect results. 26 For both molecular and antigen tests that require upper respiratory samples, the CDC has established which specimens are acceptable for SARS-CoV-2 testing (Table 2) . 27 Molecular-based diagnostic tests have been the gold standard for accurately identifying positive COVID-19 cases but the process can be lengthy if the samples must be sent to a laboratory for analysis with a turnaround time often exceeding 48 hours. 27 Antigen tests are faster to produce results but also produce more false negatives due to lower sensitivity compared to molecular diagnostic tests making it harder to manage patients appropriately. 10, [28] [29] [30] A negative antigen test may require confirmatory testing with a molecular-based diagnostic test prior to making treatment or prevention decisions. Novel CLIA-waived molecular POC tests can produce results in less than 20 J o u r n a l P r e -p r o o f 7 minutes but must be performed in CLIA-waived laboratories. [31] [32] [33] [34] SARS-CoV-2 testing technology is rapidly evolving with new technology such as the Cue COVID-19 test and Cue Monitoring System that allows healthcare providers or patients to test and connect to an application on a smart phone to read the test. 34, 35 Some of the devices that test for SARS-CoV-2 can also run tests for influenza A and B and/or group A streptococcus maximizing the tests that pharmacists may be able to offer in their pharmacies. Table 3 provides a comparison of available CLIA-waived diagnostic tests for SARS-CoV-2 at the time of writing however, it should be noted that technology is changing rapidly. [29] [30] [31] [32] [33] [34] [35] 

Best practices during a public health emergency begins with education. Similar to adoption of immunization practices, pharmacists can assume one of three roles (advocacy/education, facilitation, and testing) for SARS-CoV-2 diagnostic testing. 36 Advocacy and education are the cornerstone of best practices for a public health emergency. Pharmacists are a source of education for patients who need to understand CDC recommendations of how to protect themselves and others. 37 At the point of care and during telephone calls or telehealth visits, pharmacists should check with patients to verify they are following safety precautions. Pharmacists must model appropriate protection and ensure that proper controls are in place in their pharmacies. 37 Furthermore, pharmacists must adopt best practices for SARS-CoV-2 diagnostic testing. This includes maintaining a safe testing site with efficient workflow, following guidelines for who to test, interpreting test results, reporting and follow-up. 24, 27, [36] [37] [38] [39] [40] Important for pharmacist testing is proper training and awareness of testing guidelines for pharmacists and staff (Table 4 ). Pharmacists should understand the pathophysiology of SARS-CoV-2 and the principles of testing including the accuracy of the test. All pharmacy staff should understand good laboratory practices and cleaning of site and spaces.

Pharmacists and staff may need training on when to use and what PPE is necessary, how to properly J o u r n a l P r e -p r o o f 8 don, use, and doff PPE in a manner to prevent self-contamination, how to properly dispose of or disinfect and maintain PPE and the limitations of PPE. State/territorial health departments may be able to assist pharmacists in providing training especially in the area of properly fitting masks and face shields.

The CDC has issued guidelines for five distinct populations who should receive SARS-CoV-2 diagnostic testing including individuals with signs or symptoms consistent with COVID-19, asymptomatic individuals with recent known or suspected exposure to SARS-CoV-2 to control transmission, asymptomatic individuals without known or suspected exposure to SARS-CoV-2 for early identification in special settings, individuals being tested to determine resolution of infection, individuals being tested for purposes of public health surveillance for SARS-CoV-2. 38 Pharmacists should partner with the state/territorial health departments to understand priorities for testing in their states.

Guidance for collecting specimens is available from multiple sources. 27, [39] [40] Many SARS-Cov-2 diagnostic tests allow for patients to self-collect a specimen. Pharmacists should be able to provide proper instruction for patients to self-collect a specimen. Pharmacists will need to understand the test technology and be able to interpret results to provide education for patients. Patients will need to understand how they will received notification of results and the role of contact tracers. Patients who test positive will require notification and follow up. Patients who test negative will require notification and may require follow-up, based on symptoms and exposure to SARS-CoV-2. Pharmacists should coordinate with primary care about who will conduct the home management follow-up. Some newer laboratory platforms are using a text notification or access to a patient portal for results. However, access to results is not a substitute for post-testing education and follow-up. A positive patient who is determined to be eligible for home management will receive follow-up based on their risk for severity of disease. [41] [42] [43] [44] Typically, a telehealth follow-up should be conducted on days 4, 7, and 10 after the start of clinical illness. 43 Pharmacists should follow all applicable state reporting laws and reach out to the J o u r n a l P r e -p r o o f 9 state/territorial health department to discuss these requirements. Pharmacists partnering with laboratories and other entities will need to confirm reporting responsibilities.

Even with clarification about pharmacists' authority to order and administer tests for SARS-CoV-2 under the PREP Act, how testing might work in community-based pharmacies and how it could be scaled more broadly is evolving. [22] [23] Testing in community-based pharmacies is based on two pathways. 45 In the first, the pharmacist facilitates testing through collecting or supervising patient collecting the specimen and partnering with a laboratory for processing the specimen and conducting the test. In the second pathway, the pharmacist or patient collects the specimen and conducts the POC test with the pharmacy being registered as a CLIA-waived laboratory. Since May 8, 2020, 425 CLIA-waivers have been processed for pharmacy-based laboratories. 46 However, under these two pathways there are multiple workflows for conducting SARS-CoV-2 diagnostic testing that include differences in who assesses the patient and orders the test and where and how the specimen is collected for testing. Figure 1 and 2 depict the differences in workflows for pharmacist-based testing under these two pathways (laboratory conducts the test and pharmacist POC testing). Table 5 outlines strengths and weakness of the different workflows. In the first pathway, the pharmacist may perform the screening and assessment of patients, collect the specimen and send the specimen to the laboratory for processing. Two types of payment structures may be negotiated in this model, the laboratory or another entity pays the pharmacist for SARS-CoV-2 testing-related services or the pharmacist contracts with the laboratory or other entity to collect or supervise collection of the specimen. Depending on the contract, the pharmacist or the laboratory or other entity may conduct the patient result notification. In the pathway where the pharmacist processes the test as a CLIA-waived J o u r n a l P r e -p r o o f 10 laboratory, payment opportunities exist for payment to the pharmacy-based laboratory to conduct the test and for COVID-19 testing-related services.

Within the two pathways, different models for partnering organizations and payment for testing and pharmacist-provided testing-related services exist. The following are models of existing pharmacist ore emerging partnerships for pharmacist testing for SARS-CoV-2 at the time of manuscript writing: • Pharmacy/Pharmacist provides the location but the pharmacy is not involved in testing.

In the first model, the pharmacist may partner with the state/territorial health department or other public entity under a public-private partnership to provide testing ( Figure 3 ). Under this model, the state/territorial health department or other public entity may provide equipment for testing such as PPE or testing supplies or provide funding for testing. 47 HHS has launched public-private partnerships with community pharmacies including large community chains and some independent pharmacies. 47 The pharmacist may or may not perform the rapid test under this model; it depends on the testing used by the state/territorial health department or HHS. For example, laboratory and healthcare technology companies are included in some of the HHS partnerships with pharmacies. 47 If the pharmacist is involved with performing the rapid test, the pharmacy must submit for a CLIA Certificate of Waiver for SARS-CoV-J o u r n a l P r e -p r o o f 11 2 diagnostic testing through their state. Under this model, payment for the pharmacist testing is received through funding from the state/territorial health department or the public entity. Additionally, the pharmacy may submit claims for uninsured patients through the Health Resources and Services Administration (HRSA) COVID-19 Claims Reimbursement Program (https://www.hrsa.gov/coviduninsuredclaim). 48 This model may be desirable for pharmacists because payment is received from the state/territorial department or public entity. The large community-based pharmacy chains and some independents have adopted this model for early SARS-CoV-2 diagnostic testing. 47, [49] [50] [51] [52] In some cases, the large community-based pharmacy chains may be conducting SARS-CoV-2 diagnostic testing through a company owned health clinic that may not involve pharmacists however, it may facilitate more payment options. 49 The second model provides a platform for partnering with other healthcare entities including provider networks telehealth companies and technology companies ( Figure 4 ). In this model, it is highly likely that the provider network has providers performing the initial screening and assessment which maybe online or through telehealth and referring to the pharmacy for specimen collection and conducting the test or sending to the laboratory. If the pharmacist is using the POC test in this model, then a CLIA Certificate of Waiver will be required. However, in most of these models, the pharmacist only participates in specimen collection. The pharmacist would receive contracted payment from the partner. This model is being adopted by some of the large pharmacy chains for pharmacy/pharmacist testing. 52 However, even in this model HHS maybe providing funding to the healthcare entity which is then distributed to the pharmacy/pharmacist. Benefit of this model is that the pharmacist/pharmacy is partnering with another entity with experience in the provision of healthcare services.

In the third model, the pharmacy/pharmacist partners with a laboratory to offer home SARS-CoV-2 testing ( Figure 5 ). In this model, the patient completes an online screening and assessment which is reviewed by a licensed healthcare professional employed by the company. If the patient meets criteria for testing; a specimen collection kit is mailed to the patient and the observation of the collection is performed through a telehealth visit again by a licensed healthcare professional. Then the patient mails the specimen to the laboratory or pharmacy for processing. Kroger Health obtained their own FDA EUA for COVID-19 Home Test Home Collection Kit and is using this model for their own employees and as well as expanding to other employers, payors and organizations via a contractual relationship. 53, 54 This model may be desirable for pharmacists because of the decreased risk of exposure to patients who are sick.

In another model the pharmacy/pharmacist partners with a healthcare clinic or primary care practice to receive referrals for testing ( Figure 6 ). The practitioners at the healthcare clinic or primary care practice perform the initial screening and assessment to provide the referral to the pharmacy for specimen collection or specimen collection and testing. Payment is received from the healthcare clinic or primary care office for specimen collection and testing. This model will enable pharmacists to build relationships with other healthcare providers which could be beneficial for the advancement of other pharmacist patient care services.

In this model, a scenario is presented for pharmacists to conduct SARS-CoV-2 tests and provide COVIDrelated testing services and be paid in the Medicare program. The pharmacist registers the pharmacy as an independent clinical laboratory, and the pharmacy bills Medicare for conducting the test (Figure 7) .

The pharmacist may also partner under an incident to physician services arrangement with a physician or NPP who can bill for the pharmacist's COVID-related testing services. Again, this model may be J o u r n a l P r e -p r o o f 13 beneficial to building relationships and partnerships that could be leveraged for advancing other pharmacist patient care services. Under the last model, the pharmacy/pharmacist provides the location for another entity to assess the patient, order the test, and collect the specimen at the pharmacy, often a parking lot. The pharmacist may offer the space at no cost or receive payment for the use of the space. The pharmacist is not involved in this model of testing.

The pathways and models provide a framework for community-based pharmacy SARS-CoV-2 diagnostic testing. As the pandemic continues to evolve, the models may change especially as the role of the pharmacist in increasing testing becomes more important.

Payment for SARS-CoV-2 diagnostic testing by pharmacists may be obtained from the following sources: Billing codes may be found here https://www.cms.gov/files/document/covid-ifc-2-flu-rsv-codes.pdf. In the Medicare program, for a pharmacist to be paid for services associated with COVID-19 testing such as assessing the patient and collecting the sample, the pharmacist must have a contract with a physician or NPP, and perform the services within the pharmacist's scope of practice and state law. The contract J o u r n a l P r e -p r o o f 15 must include a financial relationship to qualify as an "incident to" physician services arrangement between the pharmacist and physician or other qualified NPP. There is also a supervision requirement where, under the public health emergency, a physician or NPP must be available immediately using realtime audio and visual technology and the service is billed by the physician or NPP using and Evaluation and Management Current Procedural Terminology (CPT) code 99211 for both new and established patients. Medicare billing codes are found in Table 6 .

Some state Medicaid agencies are considering paying pharmacists for COVID-19 services. 57 Medicaid agencies can submit a waiver amendment to pay pharmacists for services. Additionally, some states have used a Governor's Executive Order and/or legislation to secure payment for pharmacists from Medicaid and commercial payers in the state. The Governor in New York has issued such an executive order for Medicaid to pay pharmacists for SARS-CoV-2 diagnostic testing. 57 Pharmacists may contract with employers to provide COVID-19 assessment, specimen collection and testing at the workplace or pharmacy. Opportunities may exist for pharmacists to partner with state/territorial health departments or other public or private partnerships to provide and be paid for testing services.

Pharmacists are encouraged to evaluate how physicians and NPPs are being paid for services (non-Medicare patients) when negotiating with payers. 58, 59 A payer will need to recognize pharmacists as providers in their payer network in order to negotiate contracts and/or submit medical billing codes for payment. This recognition could be required per legislation/regulations or could be based on a private sector payer recognizing the value of pharmacist services and including them in their network. Payers may want to simplify coding and adopt the same coding for pharmacists that are being used in medical billing forSARS-CoV-2 diagnostic testing and related services for other healthcare professionals.

Pharmacists may have to be recognized as a "provider" in order to negotiate contracts and/or submit J o u r n a l P r e -p r o o f 16 medical billing codes for payment. Payment should be requested for patient assessment and screening (this would include collecting or supervising the collecting of the specimen), payment for specimen collection subsequent to another healthcare provider conducting patient assessment and screening, performing the laboratory test (include cost of testing supplies), reporting the results to the patient, health department and primary care provider, as appropriate, and telehealth follow-up. Table 7 provides potential relevant non-Medicare medical billing CPT codes for these service scenarios. 58, 59 The National Council for Prescription Drug Programs (NCPDP) has developed guidance for billing for SARS-CoV-2 specimen collection and conducting testing services through a secure, pharmacy dispensing system or pharmacy point of sale (POS) software. 60, 61 The NCPDP guidance can be used by pharmacy software systems to bill COVID-19 tests that are part of a medical benefit or a pharmacy benefit. For tests that are part of the medical benefit, the pharmacy will likely need to work with an intermediary organization to take the NCPDP claim and translate it for submission to the payer. Pharmacists and pharmacies will need a National Provider Identifier (NPI) number to be able to bill for COVID-19 services. Table 8 provides coding guidance for NCPDP.

Even though challenges exist for community-based pharmacists to implement SARS-CoV-2 diagnostic testing, there is a significant opportunity to impact patient care and public health, and develop collaboration with other providers. A framework for SARS-CoV-2 diagnostic testing that includes payment for services can serve as foundation for community-based pharmacists to provide services for SARS-CoV-2 antibody testing as the science and role of this test becomes well-defined.

Pharmacists are the most accessible healthcare provider and have the knowledge and skills to assume a key role in increasing SARS-CoV-2 diagnostic testing in the U.S. Active engagement of pharmacists in J o u r n a l P r e -p r o o f 17 SARS-CoV-2 testing can help to address many of the gaps in testing availability and demonstrate the value pharmacists can provide in addressing unmet health needs. Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease, 2 amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R 87635** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique *Patient assessment and specimen collection can be billed by a physician or nonphysician provider using CPT code 99211 with funds being distributed to the pharmacist under a financial relationship and who meets incident to physician billing requirements. 

World Health Organization

World Health Organization. WHO Timeline -COVID-19

Testing for COVID-19

United States Food and Drug Administration

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19

Policy for coronavirus disease 2019 tests during the pubic health emergency (revised)

FDA combating COVID-19 with medical devices

Failing the Test -The Tragic Data Gap Undermining the U.S. Pandemic Response

How to protect yourself and others

Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States

Evaluation of a community pharmacy-based influenza and group A streptococcal pharyngitis disease management program using polymerase chain reaction point-of-care testing

Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting

Pharmacist-provided rapid HIV testing in two community pharmacies

Point-of-care testing for infectious disease: Opportunities, barriers, and considerations in community pharmacy

Exploring accessibility of community pharmacy services

Evaluation of frequency of encounters with primary care physicians vs visits to community pharmacies among Medicare beneficiaries

Pharmacist as front-line responders for COVID-19 patient care. Executive Summary

S. community pharmacies as CLIA-waived facilities: Prevalence, dispersion, and impact on patient access to testing

Guidance for licensed pharmacists, COVID-19 testing, and Immunity under the PREP act

Advisory opinion 20-02 on the Public Readiness and Emergency Preparedness Act and the Secretary's declaration under the act

Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease

?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F201 9-ncov%2Finfection-control%2Fcontrol-recommendations.html Accessed

Optimizing supply of PPE and other protective equipment during shortages

Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19

COVID-19: testing times

Veritor System for Rapid Detection of SARS-CoV-2. Product Website

Sofia 2 SARS Antigen FIA

Quidel Corporations

Xpert® Xpress SARS-CoV-2

Cue Health COVID-19 test

Cue Health COVID-19 Test

Guidelines for pharmacy-based immunization advocacy and administration

Guidance for pharmacies: guidance for pharmacists and pharmacy technicians in community pharmacies during COVID-19 response

How to obtain a nasopharyngeal swab specimen

Office of the Assistant Secretary for Health. United States Health and Human Services

Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for Coronavirus Disease

Discontinuation of Isolation for Persons with COVID -19 Not in Healthcare Settings: Interim Guidance

COVID-19): Outpatient management in adults

Virtually perfect? Telemedicine for COVID-19

American Pharmacists Association and National Alliance of State Pharmacy Associations. Pharmacy Models for COVID-19 Testing

National Alliance of State Pharmacy Associations. COVID-19 Testing

United States Department of Health and Human Services. Community-based testing sites for COVID-19

COVID-19 claims reimbursement to health care providers and facilities for testing and treatment of the uninsured

COVID-19 testing

Walmart Corporation. Supporting COVID-19 drive-thru testing

Rite Aid significant expands testing

Drive-thru COVID-19 testing at Walgreens

Food and Drug Administration Emergency Use Authorization. Kroger Health COVID-19 Test Home Collection Kit

Kroger to make emergency home COVID-19 test kits available to associates

APhA urges congress to authorize pharmacists' COVID testing and immunization services under Medicare in the next pandemic bill

New York and Ohio make moves toward allowing pharmacists to bill Medicaid for COVID-19 testing

Special coding advice during COVID-19 public health emergency

CPT reporting for COVID-19 testing

National Council for Prescription Drug Program

NCPDP News Flash: New product/services identifier added to allow pharmacies to bill for specimen collection of COVID-19